Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

ABSTRACT:

Unlabelled

The RV144 HIV-1 vaccine trial demonstrated partial efficacy of 31% against HIV-1 infection. Studies into possible correlates of protection found that antibodies specific to the V1 and V2 (V1/V2) region of envelope correlated inversely with infection risk and that viruses isolated from trial participants contained genetic signatures of vaccine-induced pressure in the V1/V2 region. We explored the hypothesis that the genetic signatures in V1 and V2 could be partly attributed to selection by vaccine-primed T cells. We performed a T-cell-based sieve analysis of breakthrough viruses in the RV144 trial and found evidence of predicted HLA binding escape that was greater in vaccine versus placebo recipients. The predicted escape depended on class I HLA A*02- and A*11-restricted

SUBMITTER: Gartland AJ 

PROVIDER: S-EPMC4135964 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature